A Phase II Trial of Xevinapant in Combination with Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer

Y. Yu,I. Ganly,E. Sherman,N.Y. Lee

DOI: https://doi.org/10.1016/j.ijrobp.2024.01.059

IF: 8.013

2024-04-01

International Journal of Radiation Oncology*Biology*Physics

Abstract:Purpose/Objective(s) Patients with head and neck squamous cell carcinoma (HNSCC) who have high risk clinicopathologic factors after surgery are at high risk for locoregional recurrence despite multimodal therapy. This risk is particularly high for patients who are found to have early recurrence during preparation for post-operative radiotherapy. Xevinapant is an oral inhibitor of apoptosis (IAP) antagonist that has demonstrated early evidence of efficacy in combination with 7 weeks of radiation and cisplatin in a phase II trial, with a tolerable safety profile. A phase III trial of definitive radiation, cisplatin, and xevinapant is underway. In this phase II study, we hypothesize that the addition of xevinapant to post-operative chemoradiotherapy with weekly cisplatin will improve disease free survival for this high risk population. Materials/Methods Subjects will be eligible for trial enrollment if they have: new diagnosis of HNSCC who have undergone surgical resection of all known gross disease who meet one of the following criteria: 1) surgical margin <5mm and 2 or more intermediate clinicopathologic risk factors (T3/4, N2b-3 disease, PNI or LVI) 2) extranodal extension or positive surgical margins or 3) biopsy proven early gross recurrence prior to RT. Patients must be within 10 weeks of surgery at the time of enrollment to be eligible, and all efforts will be made to begin radiation within 6 weeks of surgery. We anticipate that >= 85% of patients will have cancers of the oral cavity. Patients with HPV-related oropharyngeal cancers are not eligible. Eligible patients will undergo PET/CT simulation to identify evidence of early recurrence. Patients will be treated with post-operative radiotherapy (60-66 Gy in 30-33 fractions), weekly cisplatin (40mg/m2), with concurrent and adjuvant xevinapant. Patients who have evidence of gross recurrence will be treated to 70 Gy / 35 fractions of radiotherapy and 7 weeks of weekly cisplatin. Xevinapant will be dosed 200 mg / m2 days 1-14 every 21 days per cycle. The trial will enroll 54 patients. The primary endpoint is 12-month disease free survival. The cumulative incidence of locoregional failure, overall, survival, treatment related adverse effects, and patient reported quality of life. Results TBD Conclusion TBD

oncology,radiology, nuclear medicine & medical imaging